LUCENTIX develops a new biosensor technology that allows patients to measure precise concentrations of analytes in a single drop of blood or saliva using a low-cost handheld device giving laboratory-quality results. Measurements that today require sample shipping, skilled personnel, tedious sample preparation and a fully equipped laboratory, can be done by patients themselves within minutes.Read More
The LUCENTIX biosensors are based on the invention of a new type of biochemical sensing molecule. A light-producing enzyme (luciferase) is engineered to change the color of the emitted light in response to changes in analyte concentration. In absence of the analyte the molecular system emits red light, while at high analyte concentration the light is blue. More information on the scientific background can be found in a publication in the journal Nature Chemical Biology.
The technology allows quantitative measurements. The color of the emitted light changes gradually from red to blue and the exact analyte concentration can be obtained from the ratio between red and blue light.
Current prototypes: The patients pricks his finger and places a drop of blood in the single-use test strip cartridge that is inserted in the LUCENTIX device. The result of the test is available in less than 5 minutes and no sample preparation is required. The result is then transmitted and displayed on the patient's smartphone.
The technology and our current prototype are featured in this video from EPFL News.
LUCENTIX has validated its technology in a number of validation studies, among others in collaboration with the University Hospital of Lausanne (CHUV). These studies demonstrated that Lucentix' technology can be used for precise quantitative measurements in patient samples and very good agreement with gold standard laboratory-based methods were found.
The platform technology can be adapted to a large number of different analytes. Biosensors for more than 10 different analytes (small molecules and proteins) have already been developed. A selection of analytes can be found in this figure; they include some of the therapeutic drugs most commonly monitored in patients.
LUCENTIX is a young start-up at the École Polytechnique Fédérale de Lausanne (EPFL). The technology underlying the biosensors was developed by Rudolf Griss and Alberto Schena in the course of their PhD studies with Prof. Kai Johnsson.
If you would like to learn more or are looking for partnerships or investment opportunities, please contact us using the form below.